Aidea Pharma(SH:688488) Xin Lang Cai Jing·2025-11-12 02:48Core Points - The stock price of Eddie Pharmaceuticals increased by 2.13% on November 12, reaching 14.87 CNY per share, with a market capitalization of 6.257 billion CNY [1] - The company has seen a year-to-date stock price increase of 89.19%, but has experienced slight declines in the last 5, 20, and 60 trading days [1] - Eddie Pharmaceuticals reported a revenue of 552 million CNY for the first nine months of 2025, representing a year-on-year growth of 84.83% [2] Company Overview - Eddie Pharmaceuticals, established on December 15, 2009, and listed on July 20, 2020, is based in Yangzhou, Jiangsu Province [1] - The company's main business involves the exploration, research, and sales of innovative chemical drugs and human-derived protein products, with revenue contributions from human-derived proteins (41.11%), new drugs (35.69%), diagnostic equipment and reagents (13.62%), and generic drugs (9.47%) [1] - The company operates within the pharmaceutical and biotechnology sector, specifically in the biopharmaceuticals category [1] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 1.55% to 12,100, with an average of 34,709 circulating shares per shareholder, a decrease of 1.53% [2] - The company has distributed a total of 20.16 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] - New institutional shareholders include Xingquan Commercial Model Mixed Fund and Huatai-PineBridge Healthcare Mixed Fund, while some previous shareholders have exited the top ten list [3]